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Abstract
Anthracyclines are included in clinical treatments against various malignancies, but severe cardiotoxic side-effects and the development of
resistance mechanisms limit their usefulness. Many aspects of the cellular response to anthracyclines remain debated. The status of the main
regulator of iron homeostasis, namely the RNA-binding activity of iron regulatory proteins (IRPs), has been assessed herein for two types of
human tumor cells and their derived doxorubicin-resistant sublines. IRPs were always fully activated in the latter, whereas only partial
activation occurred in the former. Doxorubicin exposure reversibly inactivated IRP1 in small cell lung carcinoma (GLC4) and myelogenous
leukemia (K562) cell lines, but was without effect in their derived doxorubicin-resistant sublines. In contrast, adding doxorubicin to cytosolic
fractions of untreated cells or to purified IRPs led to the irreversible alteration of the RNA-binding activity of IRP1. In these different
conditions, interaction between doxorubicin and the iron regulatory system disturbs iron metabolism, and cells having developed a resistance
mechanism are tuned to maximize the iron supply. The results reported herein may lead the path toward a better therapeutic management of
cancer patients receiving doxorubicin by discriminating between the antiproliferative and cardiotoxic properties of this anthracycline.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Anthracycline treatments are extremely valuable tools in
various cancer chemotherapies. In contrast to their large
clinical use, the intricate cellular responses to anthracyclines
do not provide a clear understanding of their cytostatic and
cytotoxic functions against malignant cells [1]. From a
variety of proposed mechanisms, the targeting of nuclear
DNA seems a necessary step to stop highly proliferating
cells: the quinone tetra-ring is a good intercalating chemical
and anthracyclines interfere with the proper function of
DNA-modifying enzymes such as topoisomerase II and
helicases [2]. Inhibition of DNA synthesis and DNA dam-
age leading to cell death ensue. However, for these steps to
occur, anthracyclines must enter the cells and be properly
directed to the nucleus following a pathway that remains to
be fully elucidated.
Other physiological perturbations, such as membrane
damage, impairment of some signal transduction path-
ways, and deregulation of calcium homeostasis, may result
from exposure of cells to anthracyclines. Generation of
free radicals is also likely to play a role in inducing apop-
tosis [3]. All of these mechanisms have been evoked to
explain the main drawback of the clinical use of anthra-
cyclines, namely, the severe and even fatal cardiomyop-
athy associated with infusion of these drugs [4]. Never-
theless, the benefits of anticancerous therapies including
anthracyclines such as doxorubicin (AdriamycinR), dau-
norubicin, or epidoxorubicin outweigh the risks, so that
accompanying compounds aimed at minimizing cardiotox-
icity are actively sought, in addition to the one already in
use: indeed, the clinically approved strong iron chelator
dexrazoxane (ICRF-187, ADR-529) appears to provide
protection against cardiovascular injury in some studies
[5]. Another compound, the antioxidant (and lipid low-
ering) probucol prevents doxorubicin-induced heart failure
in rats [4].
From the available data, free radical generation medi-
ated by catalytic iron is a potential underlying cause of
both the cytostatic and cardiotoxic effects of anthracy-
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clines. The relationship between iron metabolism and
doxorubicin cardiotoxicity has been studied with cardiac
biopsies and cardiomyocytes (Refs. [6,7] and references
therein). A rationale for the role of iron in the genotoxic
properties of anthracyclines has also been proposed
[8,9].
A major regulatory process of iron fluxes in metazoan
cells depends on the interaction of specialized proteins, the
iron regulatory proteins (IRP1 and IRP2), with untranslated
cis-sequences, the iron responsive elements (IRE), of target
mRNA [10,11]. Translation of the ferritin subunits and of
the transferrin receptor depends on the IRP–IRE system.
Depleted iron stores and limited cellular uptake favor the
IRP–IRE interaction, whereas fulfillment of the iron meta-
bolic demand disrupts it, by converting IRP1 into an
enzyme (cytosolic aconitase) unable to bind RNA and by
priming IRP2 for degradation by the proteasome [10,11].
Cellular conditions other than variation of the available iron
and including oxidative and nitrosative stresses, target the
iron regulatory system with widespread pathophysiological
consequences [12,13].
The potential involvement of deregulation of iron homeo-
stasis in the clinical usefulness or deleterious properties of
anthracyclines justifies studying the behavior of the iron
regulatory system of metazoan cells challenged with anthra-
cyclines. We have thus compared the IRP activity of two
human cell lines that have been previously characterized
with respect to their antioxidant potential [14] and for which
doxorubicin-resistant sublines are available. The results, and
their dependence with the doxorubicin concentration, have
been contrasted with the effects of the direct interaction
between the drug and IRP.
2. Materials and methods
2.1. Cell cultures and treatments
The small cell lung carcinoma GLC4 and erythroleuke-
mia K562 human cell lines were cultured in RPMI 1640
(Life Technologies, St. Quentin en Yvelines, France) with
10% fetal bovine serum (heat inactivated in the case of
K562) and 2 mM glutamine in a humidified atmosphere of
95% air and 5% CO2 at 37 jC. Cultures of the resistant
sublines were supplemented with 3 AM doxorubicin every 3
weeks. Before experimental use, they were cultured for 1
week without doxorubicin. IC50 values (50% inhibitory drug
concentrations) were determined by the MTT (Sigma)
colorimetric assay [15] as 1 and 25 AM for GLC4S and
GLC4
R cells, respectively, and 0.3 and 165 AM for K562S
and K562R cells, respectively. These cells differ in their
resistance profiles: resistance in K562R is mainly carried out
by PgP (P-glycoprotein) overexpression, whereas GLC4
resistance relies on all PgP, LRP, and MRP [16,17].
Doxorubicin (Laboratoires Roger Bellon, Paris, France)
exposure of the different cell lines was carried out for 24
h at 37 jC at concentrations not exceeding the dose in-
ducing a 50% decrease of viability under the same con-
ditions.
HeLa, human fibroblasts, and THP1 monocytes were
kind gifts from Dr. M.-J. Richard (LBSO, Grenoble,
France).
2.2. Preparation of cytosolic extracts
Cells were harvested by centrifugation (2 min, 2660 g,
4 jC) and the pellet was washed twice with 5 ml phosphate-
buffered saline. The pellet corresponding to 5 106 cells
was rinsed with 250 Al of 10 mM HEPES, 1.5 mM MgCl2,
10 mM KCl, 0.2 mM phenylmethylsulfonyl fluoride, 0.5
mM dithiothreitol (pH 7.9), centrifuged as before and
resuspended in 250 Al of the same hypotonic buffer. The
suspension was kept for 15 min at 4 jC, homogenized and
0.5% (v/v) Nonidet P-40 was added. After thorough mixing
for 10 s, the lysed cells were centrifuged for 30 s at
16000 g. The supernatant was recovered and assayed
for its protein content.
2.3. Enzymatic and other assays
Recombinant human IRPs were produced and purified
by an established protocol [18]. Depletion of the [4Fe–4S]
cluster to provide fully active IRP1 has been described
[19]. Aconitase activity of IRP1 was measured with cis-
aconitate as substrate [18] following the decrease in
absorbance at 240 nm (Hewlett-Packard 8452 spectropho-
tometer) in air-tight cuvettes evacuated with argon. The
IRE-binding activity was carried out as previously
described [18], in an argon chamber for anaerobic assays.
The a-[33P]UTP-labeled RNA probe corresponded to the
human H-ferritin stem-loop IRE with the GAGACCG-
GAAUUC sequence on the 5V side and the AUCCU one
on the 3V side giving a transcript of 41 nucleotides. In all
IRE-binding activity assays, excess of IRE was provided
and checked by the large radioactivity of the fast migrating
bands on the gel. These conditions apply to assays carried
out in the presence of doxorubicin that was reported to bind
to RNA [20] but whose concentration was never large
enough as to titrate out the excess of RNA probe. The
ferritin content of cytosolic extracts was determined by a
standardized sandwich enzyme immunoassay with rabbit
anti-human ferritin antibodies (Dako S.A., Trappes, France):
these results were obtained by Dr. J.-C. Renversez (DBI,
CHU Grenoble, France). The implementation of electron
paramagnetic resonance spectroscopy has been described
elsewhere [18]. The release of iron from IRP1 in the presence
of doxorubicin was measured by absorption spectroscopy
using e600 nm = 11400 M
 1 cm 1 [21]. Given the complex-
ity of the interactions between iron and doxorubicin [22], this
value may not be very accurate, but it provided estimates in
agreement with electron paramagnetic resonance measure-
ments (see Results).
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2.4. Synthesis of doxorubicinol
Doxorubicinol was produced by the chemical reduction
of doxorubicin with potassium borohydride. Fifty micro-
liters of 20 mM doxorubicin (Aldrich Chem Co., Milwau-
kee, WI) in 50 mM HEPES (pH 7.6) was allowed to react
with 4 Al of 0.5 M KBH4 (Sigma Chem Co., St. Louis, MO)
for 2 h at ambient temperature: the solution rapidly turned
darker than the initial bright red color and was extracted
with 50 Al of chloroform. The aqueous fraction was
removed and freeze-dried. The red pellet was solubilized
in 10% (v/v) acetonitrile, 0.1% phosphoric acid in water and
purified by high-performance liquid chromatography (Kon-
tron) on a reverse phase 0.8 25 cm C18 column (Dr. H.
Knauer, Bad Homburg, Germany). Elution was carried out
under isocratic conditions with 30% (v/v) acetonitrile, 0.1%
phosphoric acid in water and the products were detected
with an on-line Bio-Tek SFM25 spectrofluorimeter with 470
and 585 nm excitation and emission wavelengths, respec-
tively. Under these conditions, the two diastereoisomers of
doxorubicinol were produced but have not been separated.
The retention times of doxorubicin and doxorubicinol were
12 and 10 min, respectively.
2.5. RNA preparation and reverse transcription–polymer-
ase chain reaction (RT-PCR)
Total RNA from GLC4 cells was prepared with the
guanidinium hydrochloride method (High Pure RNA iso-
lation kit, Roche Diagnostics). RT and amplification by the
PCR were carried out with AMV reverse transcriptase and a
mixture of Taq and Pwo DNA polymerases (Titan one tube
RT-PCR system, Roche Diagnostics), respectively, using h-
actin as a standard. cDNA synthesis was for 30 min at 50
jC. For amplification, hybridization was at 50 jC and
elongation at 68 jC. The amount of total RNA used as
template and the number of amplification cycles needed to
get a proportional signal were determined in preliminary
experiments. The transcript corresponding to the human
transferrin receptor was detected as a 684-bp DNA fragment
with primers:
TfR-F: GGCAGTTCAGAATGATGGATCAAGC; and
TfR-R: GCCTTACTATACGCCACATAACCCCC.
The semiquantitative measurement of the glutathione
(GSH)-dependent formaldehyde dehydrogenase (FDH) tran-
script used:
FDH1: GCCTATACCCTGAGTGGAGCTGATCCT-
GAGGGT; and
FDH2: TTTCCCTTGAGTGACTCTTATCTTCTG.
These primers amplify a 217-bp fragment from FDH
cDNA. To ensure specificity, FDH2 overlaps an intron–
exon junction on genomic DNA and both primers were
chosen in regions significantly variable among the human
alcohol dehydrogenase gene family. The products of the RT-
PCR experiments were analyzed on 3% QA-Agarose Multi-
purpose (Q Biogene) gels run with Tris–Borate–EDTA
(TBE) buffer and stained with ethidium bromide. The
stained gels were UV irradiated (312 nm), the resulting
picture was recorded with a CCD camera (N50 Bio-Capt,
Vilber Lourmat, Marne-la-Valle´e, France) and the bands
were quantified with an image analysis software (Scion
Image, Scion Co., Frederick, MD).
2.6. Statistical analysis
Data are expressed as meanF S.E. for more than three
experiments.
3. Results
3.1. Effect of doxorubicin on the induction of the major
formaldehyde detoxification gene
Iron may catalyze the production of active formaldehyde
from uncharacterized intracellular components under oxida-
tive stress such as that induced by doxorubicin treatments
[9]. In the normal intracellular environment where milli-
molar concentrations of GSH are present, free formaldehyde
is expected to be trapped by GSH as hydroxymethyl-GSH
and other species in rapid equilibrium [23]. GSH-dependent
FDH is the main scavenger of hydroxymethyl-GSH, that is
converted into formate with GSH regeneration. The possi-
bility that resistance to doxorubicin may be mediated, at
least in part, by overexpression of the GSH-FDH gene was
evaluated by RT-PCR (Fig. 1). In GLC4 cells, the absolute
Fig. 1. Relative glutathione-dependent FDH mRNA levels in GLC4 cells.
Total RNA of GLC4
S (lanes 2 and 3) and GLC4
R (lanes 4 and 5) was analyzed
by RT-PCR as described in Materials and methods. 2.5-fold more RNAwas
used as template to detect the glutathione-dependent FDH transcript (lanes
2 and 4) than for h-actin (lanes 3 and 5). Lane 1 is for markers, with
selected values indicated on the left. The contrast of the ethidium bromide-
stained gel is inverted for clarity. This figure represents a typical experiment
and statistically meaningful values for the measured intensities are given in
the text.
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amount of GSH-FDH transcripts is relatively small com-
pared to h-actin, but no major differences were detected
between doxorubicin-sensitive and -resistant cells: the GSH-
FDH mRNA content of the parent cell line was 170F 13%
of that of the resistant one. Upon doxorubicin treatments,
decreased expression of the GSH-FDH gene was observed
in both cell lines.
3.2. IRP activity of doxorubicin-sensitive and -resistant cell
lines
Comparison of the IRE-binding activities present in
doxorubicin-sensitive and -resistant K562 cells is given in
Fig. 2. Without suitable antibodies allowing selective immu-
noprecipitation, it is not possible to discriminate between
human IRP1 and IRP2 that co-migrate in these mobility
shift assays: in the following, only the combined IRP1/IRP2
activity is considered.
Addition of 2% (v/v) 2-mercaptoethanol to these assays
activates all functional IRP present in the samples [10,13]:
by comparison with the activity obtained without 2-mer-
captoethanol addition, the procedure provides estimates of
the proportion of total IRP that is active in the cells.
Although the total amount of IRP is roughly the same in
cells of identical parental lineage, the proportion of active
IRP is close to maximal (95F 8%) in resistant cells,
whereas it is only a fraction of the total in sensitive cells
(59F 8%). Similar results were obtained with GLC4 cells.
In these experiments with cultured cells not exposed to
doxorubicin, the growth rate of sensitive cells is at least
equal to that of resistant cells and the full activation of IRP
in the latter cannot be ascribed to increased cell proliferation
[24] or to iron withdrawal triggered by doxorubicin chela-
tion of the available metal. IRPs are redox-sensitive proteins
and activity measurements were carried out under controlled
conditions. However, the proportions of active IRP remained
the same whether the assays were carried out under argon in a
glove box or on the bench without monitoring or controlling
the redox conditions.
As expected from the activity of IRP, the ferritin content
of K562S (1.05F 0.05 ng/Ag cytosolic proteins) was larger
than that of K562R (0.51F 0.05 ng/Ag). Indeed, according
to the general model of IRP regulation [10,12,13], the larger
amount of activated IRP in K562R (Fig. 2) should more
efficiently repress ferritin biosynthesis than the smaller
proportion of active IRP in K562S. Both sensitive and
resistant cells were exposed until harvest to increasing
concentrations of doxorubicin up to that maintaining only
50% of the cell population after 24 h at 37 jC. Increasing
amounts of doxorubicin decreased the IRE-binding activity
of IRP in GLC4
S cells (Fig. 3), without significant changes of
the total amount of IRP (93F 12% for six independent
measurements of total IRP after 24 h of exposure to 1 AM
doxorubicin). For instance, only 72F 5% of active IRP
Fig. 2. IRP activity of doxorubicin-sensitive and -resistant K562 cell lines.
Electrophoresis mobility shift assays on PAGE 5% in 0.25TBE were
carried out with 5 Ag of cytosolic extracts prepared from K562S (lanes 1
and 2) and K562R (lanes 3 and 4) cells to separate the IRE–IRP complex
(arrow) and the free probe (dotted arrow). Assays were supplemented with
2% 2-mercaptoethanol to evidence the total IRP activity present in the
samples (lanes 2 and 4).
Fig. 3. IRP activity of doxorubicin-treated GLC4
S cells. Electrophoresis
mobility shift assays were carried out as in Fig. 2 with 5 Ag of cytosolic
extracts. GLC4
S cells were treated with 0 (lanes 1 and 2), 0.5 AM (lanes 3
and 4), or 1 AM (lanes 5 and 6) doxorubicin 24 h before harvest. Assays
were supplemented with 2% 2-mercaptoethanol in lanes 2, 4, and 6, and
they were carried out under argon (upper gel) or not (lower gel). Only bands
of the IRE–IRP complex are shown.
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remained after a 24-h treatment of GLC4
S cells with 0.5 AM
doxorubicin. In contrast, exposure of resistant cells to 12.5
AM doxorubicin for 24 h had no statistically significant
effect on IRP activity.
The amounts of transferrin receptor transcripts were
measured by RT-PCR in both GLC4
S and GLC4
R cells treated
with increasing concentrations of doxorubicin (not shown).
No variations were detected for GLC4
R cells, in agreement
with the constant activity of IRP. In contrast, the transferrin
receptor transcript concentration decreased with the doxor-
ubicin dose for GLC4
S cells. Since IRP activity stabilizes the
transferrin receptor messenger RNA through IRE binding,
this result is in line with the decreased IRP activity measured
in these experimental conditions. Ferritin concentrations in a
single set of doxorubicin-treated GLC4
S cells did not give
reliable variations as a function of the dose: ferritin expres-
sion is regulated in different ways under stress conditions
[25], and this may contribute to the apparent discrepancy
between IRP activity status and ferritin concentration with
this particular cell line.
3.3. Effect of doxorubicin on the IRP activity of cell extracts
To examine whether doxorubicin was directly acting on
IRP when applied to GLC4
S cells, cytosolic extracts were
incubated with various amounts of the anthracycline. The
proportion of active IRP was found to vary slightly, but
without a significant and reproducible trend (Fig. 4, lanes 1,
3, and 5). These observations were extended to extracts
prepared from HeLa cells, human fibroblasts, and THP1
monocytes. However, the total amount of IRP in GLC4
S
extracts that could be activated with 2% 2-mercaptoethanol
steadily decreased upon treatment with doxorubicin with a
15F 5% loss at 1 AM doxorubicin (Fig. 4, lanes 2, 4, and 6).
These results were obtained by measuring IRE-binding
activities either aerobically or anaerobically. Larger doxor-
ubicin concentrations up to 5 AM further decreased the
amount of IRP that was activated by 2% 2-mercaptoethanol,
but IRP inactivation was far from being complete after
reaction for 1 h either at 37 jC or ambient temperature.
Thus, IRP is irreversibly — with respect to in vitro
activation with 2% 2-mercaptoethanol — inactivated by
doxorubicin in cell extracts (Fig. 4), in contrast to the
constant total IRP activity present in intact cells treated
with increasing amounts of doxorubicin (Fig. 3). The
variable IRP activity, measured in the absence of 2-mercap-
toethanol, in extracts treated with doxorubicin is then
probably due to the combination of the possible activation
of IRP and of the decreased total amount of activation-
competent protein.
Doxorubicinol is the major human metabolite of doxor-
ubicin [26] corresponding to reduction of the ketone on C-
13 (lateral chain) into a secondary alcohol. The purified
mixture of doxorubicinol diastereoisomers was added to
GLC4
S cytosolic extracts. The total IRP activity measured in
the presence of 2% 2-mercaptoethanol also decreased upon
doxorubicinol additions: an experiment with 5 AM doxor-
ubicin led to a 12% loss of activity after 1 h of reaction at
ambient temperature, whereas the same amount of doxor-
ubicinol decreased the activity by 35%. A similar experi-
ment carried out with cytosolic extracts of GLC4
R did not
evidence any irreversible decrease of IRP activity.
3.4. Effect of doxorubicin on pure IRP
From the above experiments, the consequences on IRP
activity of exposing either GLC4 cells or extracts to doxor-
Fig. 4. IRP activity of GLC4
S lysates in the presence of doxorubicin. Ten
micrograms of cytosolic extracts was incubated for 1 h at 37 jC with 0
(lanes 1 and 2), 1 AM (lanes 3 and 4), or 5 AM (lanes 5 and 6) doxorubicin
before measuring the IRP activity in the absence (lanes 1, 3, and 5) or
presence (lanes 2, 4, and 6) of 2% 2-mercaptoethanol under argon (upper
gel) or not (lower gel). As stated in the text on the basis of several similar
experiments, the amounts of active IRP in the absence of 2-mercaptoethanol
(lanes 1, 3, and 5) do not significantly vary, whereas those measured with 2-
mercaptoethanol (lanes 2, 4, and 6) decrease with the dose of doxorubicin
as shown on the histograms plotting the radioactive signal intensity of each
retarded band for this particular experiment.
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ubicin are different. To clarify the way doxorubicin interacts
with the posttranscriptional iron regulatory system, reactions
of pure human IRP with doxorubicin were examined.
The as-prepared recombinant human IRP1 is the cyto-
solic aconitase enzyme [18]. The corresponding activity of
the pure protein was measured anaerobically over time in
the presence of a 12-fold excess of doxorubicin (Fig. 5).
Only a very slow decrease of activity occurred. The same
experiment was carried out by replacing doxorubicin with
doxorubicinol without major evolution of aconitase activity
in this case also. When no efforts were made to exclude
oxygen from these assays, the aconitase activity was pro-
gressively lost over time, at a faster rate in the case of
reaction with doxorubicinol (Fig. 5). Since aconitase is a
[4Fe–4S] enzyme, its activity relies on the presence of the
intact iron–sulfur cluster. The release of iron in the reaction
with doxorubicin was thus measured both by electron para-
magnetic resonance and absorption spectroscopies under the
above conditions: it was found that a single iron atom, at
most, per IRP1 molecule was expelled within the first 2–3
h, but the presence of oxygen increased the rate of release.
According to the substoichiometric loss of cluster (there
are four iron atoms per protein molecule), the decrease of
aconitase activity was not correlated with any increase in
IRE-binding activity (Fig. 6). However, the total IRE-bind-
ing activity that could be revealed by treating pure IRP1
with a large excess of reducing 2-mercaptoethanol
decreased upon exposure to either doxorubicin or doxoru-
bicinol in the presence of oxygen (Fig. 6A). This loss of
total IRE-binding activity seemed larger when cis-aconitate
(the reaction intermediate between the substrate and the
product of the aconitase reaction) was added to the reaction
(Fig. 6B).
To explore the possibility that a cell component may
interfere with the doxorubicin-induced inactivation of
IRP, pure recombinant IRP1 (3 ng) was added to soluble
extracts of GLC4
S (2 Ag of proteins). Doxorubicin (2 AM)
had a minor effect on the IRE-binding activity in the
absence of 2-mercaptoethanol, but the decrease of total
IRE-binding activity revealed with 2% 2-mercaptoethanol
was also observed in these experiments. Interestingly, this
result was obtained both when [4Fe–4S] IRP1 (aconitase)
or apo-IRP1 (the IRE-binding form prepared in vitro) was
added to the extracts. In contrast, the IRE-binding activity
of recombinant human IRP2 was insensitive to the same
treatment. This strongly suggests that the doxorubicin
effects observed in the present experimental setup specif-
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Fig. 5. Aconitase activity of doxorubicin- or doxorubicinol-treated pure
human IRP1. Ten micromolars of pure recombinant human IRP1 was
incubated with 120 AM doxorubicin or 120 AM doxorubicinol. Relative
aconitase activities left after reaction with doxorubicin (circles) or
doxorubicinol (squares) under argon (closed symbols) or air (open symbols)
are plotted as a function of time.
Fig. 6. IRE-binding activity of doxorubicin- or doxorubicinol-treated pure
human IRP1. (A) Ten micromolars of pure recombinant human IRP1 was
incubated with 120 AM doxorubicinol and the IRE-binding activity of 30 ng
of protein was measured at the start of the experiment (left) and after 2 h
(right), without (lanes 1 and 3) or with (lanes 2 and 4) 2% 2-
mercaptoethanol. IRP1 is initially only marginally active as an IRE-
binding protein (lane 1 vs. lane 2) and remains so during the experiment,
although it is irreversibly modified (lane 2 vs. lane 4). (B) Ten nanomolars
of pure recombinant human IRP1 was incubated for 1 h without (lanes 1, 2,
5, and 6) or with (lanes 3, 4, 7, and 8) 5 AM doxorubicin, without (lanes 1–
4) or with (lanes 5–8) 10 AM cis-aconitate before measuring the IRE-
binding activity without (lanes 1, 3, 5, and 7) or with (lanes 2, 4, 6, and 8)
2% 2-mercaptoethanol. The effect of cis-aconitate on the irreversible loss of
IRE-binding activity is observed by comparing the intensities of the
retarded bands in lanes 4 and 8.
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ically apply to IRP1, with little or no involvement of
IRP2. Such conclusion agrees with the constant amount
of total IRP found in the different cell lines upon
doxorubicin additions (Fig. 3), as regulation of IRP2
activity would lead to variable concentrations of the
protein [10].
4. Discussion
4.1. Is up-regulation of formaldehyde oxidation responsible
for cellular resistance to doxorubicin?
Some of the structurally characterized complexes between
anthracyclines, including doxorubicin, and DNA oligonu-
cleotides with internal guanine are cross-linked via a
bridging methylene group between daunosamine N3V and
the 2-amino group of the guanine base [9,27,28]. The
source of the formaldehyde molecule, that is the likely
precursor of the methylene group, is not well established,
but in vitro experiments showed that reduced iron, oxy-
gen, and mono-carbon-releasing substrates such as amines
and lipids [8,9] can produce formaldehyde. The physio-
logical bearing of this molecular mechanism is borne out
by the increased cytotoxicity of formaldehyde-derived
anthracyclines [29,30]. Formaldehyde is considered to be
detoxified by GSH-dependent FDH [31] and increased
activity of the enzyme may participate in decreasing the
targeting of anthracyclines to DNA’s guanines. Instead, the
level of gene expression in resistant cells is lower than in
sensitive ones (Fig. 1), thus excluding up-regulation of
GSH-dependent FDH as part of the resistance mechanism.
Mammalian GSH-dependent FDH, in contrast to microbial
homologs, may not be induced by its substrate [32] or the
reaction rate between newly formed formaldehyde and
doxorubicin is fast enough for the reactive moiety to
escape the enzyme action. In this respect, recent experi-
ments have led to the proposal that GSH-dependent FDH
may control the levels of nitroso-thiols rather than that of
formaldehyde [33]. In any case, the present data exclude
large changes of GSH-dependent FDH gene expression in
the cellular response against doxorubicin action.
4.2. Contribution of the iron regulatory system to the
resistance mechanism against doxorubicin
The relationship between disruption of iron homeostasis
and the action mechanism of anthracyclines is beginning to
unfold [6–9]. IRPs are exquisite detectors of the intra-
cellular iron that can be readily mobilized for biosynthetic
needs. Any shortage, or inconsistencies in the chemical
form, of iron induces binding to specific sequences of the
untranslated regions (IRE) of target mRNA. The IRE–IRP
interaction regulates iron homeostasis and it has been
measured herein in doxorubicin-resistant cells for compar-
ison with their parent cell lines. The implemented growth
conditions for GLC4
S and K562S cells do not induce iron
starvation because only a fraction of IRP is active in these
cells (Fig. 2). Resistant cells grow at approximately the
same rate as sensitive ones, an observation that excludes
any shortage of externally available iron as the cause of
full activation of IRP. Instead, resistant cells scavenge
easily mobilized iron from IRP detection by a mechanism
that may decrease the deleterious catalytic action of the
metal.
Treatment of resistant cells with doxorubicin neither
changes the total amount of IRP nor decreases the propor-
tion of active IRP that is maximal in the absence of
doxorubicin. In contrast, exposure of sensitive cells to
doxorubicin does decrease the fraction of active IRP, but
the amount of protein that can be activated in vitro remains
the same. The loss of active IRP cannot be assigned to the
chelating properties of doxorubicin because activation, and
not inhibition, of IRP should occur upon iron withdrawal.
On the contrary, the decreased proportion of active IRP in
the presence of doxorubicin is usually associated with an
increase of the intracellular iron detected by the regulatory
system. Release of ferritin iron by the drug with contribu-
tions from reducing enzymes is a possible mechanism [34],
but several alternatives may be considered such as
decreased metabolic rates [35] or increased uptake by
transcriptional overexpression of the transferrin receptor
[36]: in this respect, the transferrin receptor transcripts
were systematically more abundant in GLC4
R cells than in
GLC4
S ones as measured by RT-PCR. In all these cases,
changes in the proportion of active IRP1 may be part of the
strategy of the cells to cope with the perturbations afforded
by doxorubicin.
It may be worth mentioning here that resistance mecha-
nisms have often been associated either with increased
xenobiotic efflux mediated by energy-dependent pumps
[37–39] or with lowered input rates [40,41]. GLC4
R cells
were reported to accumulate lower amounts of anthracy-
clines than sensitive ones with a different distribution
including trapping into vesicles [16,42]. This difference
was taken into account by treating cells with similar
fractions of the lethal doses, which should roughly equili-
brate intracellular concentrations of doxorubicin in sensitive
and resistant cells, although the role of intravesicular
anthracyclines in drug resistance is not known [43]. Fur-
thermore, K562R cells exclusively overproduce PgP, and
GLC4
R cells develop resistance to anthracyclines by over-
expressing the genes of several efflux pumps [17]. These
different mechanisms should affect cellular metabolism in
different ways. Indeed, MRP-associated pumps transport
GSH adducts, whereas PgP exports free xenobiotics: still
the IRP status is similar both in GLC4 and K562 cells and in
doxorubicin-resistant lines. Overall, the observed effects on
IRP are most probably reflecting different handling of the
iron resources between sensitive and resistant cells, rather
than significantly different intracellular concentrations of
doxorubicin.
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4.3. Doxorubicin impacts the iron regulatory system in
different ways: relevance for the antiproliferative and
cardiotoxic properties of the anthracycline
The total amount of IRP activity in doxorubicin-sensitive
and -resistant cells, elicited in vitro by addition of 2-
mercaptoethanol to the assays, is roughly the same and
does not vary when sublethal drug concentrations are added
to the cultures (Figs. 2 and 3). In sharp contrast, doxorubicin
or doxorubicinol decrease the IRP activity of the cell lysates
measured in the presence of 2-mercaptoethanol (Fig. 4). The
same holds true when pure IRP1 is substituted for the
extracts, if oxygen is also present (Fig. 5), and the aconitase
substrate, that is also an iron chelator, seems to enhance the
loss of IRP1 activity (Fig. 6).
Qualitatively similar results were reported with human
myocardial cytosolic extracts that were shown to produce
doxorubicinol from doxorubicin and NADPH that mobi-
lized iron [44] and irreversibly decreased IRP1 activity
[45]. These experiments laid the foundation of an iron-
driven mechanism of doxorubicin cardiotoxicity mediated
by doxorubicinol and involving depression of the regula-
tory function of IRP1 [6,46]. In agreement with this
proposal, inhibition of aldo-keto reductase activity by
phenobarbital decreased doxorubicinol and creatine kinase,
a marker of cardiac damage, in rat serum [47]. In non-
cardiac cells, increased alcohol metabolites participate to
resistance against anthracyclines [48,49], hence suggesting
that the balance between cardiotoxicity and tumor anti-
proliferation may be related to the anthracycline/13
hydroxyl-derivative ratio [50]. Furthermore, scavenging
iron with dexrazoxane (ICRF-187) affords valuable cardi-
oprotection against anthracycline damage, including in
clinical settings [5], despite some evidence of deleterious
side-effects [4]. More recently, exposure of a rat heart cell
line to doxorubicin activated IRP at low doses and
repressed it at high doses [7]. On the basis of the applied
drug concentrations [less than 1 AM for GLC4S (this work)
and up to 10 AM for the rat H9c2 line [7]], the different
sensitivities displayed by these cell lines may explain the
qualitative differences of the dose responses.
Considering the different outcomes between doxorubicin
treatments applied to cell cultures (Fig. 3) or to lysates (Fig.
4) (reversible and irreversible alterations of IRE-binding
activity of IRP, respectively), different mechanisms of
doxorubicin action seem relevant in the two sets of con-
ditions. Doxorubicin or its derivative doxorubicinol do not
convert purified cytosolic aconitase into its IRE-binding
form (Figs. 5 and 6) because reasonably low concentrations
of these chemicals are only able to remove a single iron
atom from the enzyme. However, they are far more efficient
at irreversibly inactivating the protein (Fig. 6). Accordingly,
the IRE-binding activity of cell lysates treated with these
anthracyclines (Fig. 4) is irreversibly lost in a dose-depend-
ent way. These data may be explained by the dual reactivity
of doxorubicin(ol) acting as a chelating agent for the labile
iron of aconitases (and possibly other iron–sulfur proteins)
and as a superoxide generator through redox cycling of the
quinone moiety. Such mechanisms would be responsible for
the inactivation of aconitase (Fig. 5) and the irreversible
modification of the protein (Figs. 4 and 6), respectively.
These conclusions are in general agreement with those
derived from studies of the iron–anthracyclines interferen-
ces in human cardiomyocytes lysates [44,45] or in a rat
model cell line [7].
As external (and maybe vesicular) doxorubicin induces a
mediated cellular response, including through reactive oxy-
gen species [51], some of the elicited signals may modify
IRP1 activity. Such occurrence of signaling pathways tar-
geting IRP1 is not without precedent [18,52] and may be the
rule rather than the exception in modulating the activity of
the iron regulatory system [13]. Quantitative differences in
the signal elicited by anthracyclines among various cell
types may explain the slightly different effects on the iron
regulatory system (Ref. [7], this work). In view of the
important pathophysiological consequences of the break-
down of iron homeostasis, including at different stages of
neoplasms’ development [53], a further exploration of the
relationships between iron fluxes and the toxicological
efficiency of selected drugs, including anticancer agents
such as anthracyclines, seems appropriate.
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